Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus (Q58448474)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Yan-Ling He

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Denise Serra

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Yibin Wang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Joelle Campestrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Gilles-Jacques Riviere

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Sherwyn Schwartz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Jace C Nielsen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Monica Ligueros-Saylan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

577-588

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17596103%20AND%20SRC:MED&resulttype=core&format=json

Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects

1 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200746070-00003

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

21 January 2018

1 reference

12 December 2020

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

12 December 2020

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

1 reference

12 December 2020

GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans

1 reference

12 December 2020

Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man.

1 reference

12 December 2020

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

12 December 2020

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

1 reference

12 December 2020

Altered homeostatic adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

1 reference

12 December 2020

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

12 December 2020

Therapeutic strategies based on glucagon-like peptide 1.

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

12 December 2020

Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians

1 reference

12 December 2020

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

12 December 2020

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

12 December 2020

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

12 December 2020

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

12 December 2020

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans

1 reference

12 December 2020